Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Queensland Health
QuintilesIMS
Federal Trade Commission
Cantor Fitzgerald
Moodys

Generated: September 23, 2019

DrugPatentWatch Database Preview

Patent: 9,562,038

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,562,038
Title:Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus
Abstract: The present invention is directed to new bifunctional compounds and methods for treating HIV infections. The bifunctional small molecules, generally referred to as ARM-HI\'s, function through orthogonal pathways, by inhibiting the gp120-CD4 interaction, and by recruiting anti-DNP antibodies to gp120-expressing cells, thereby preventing cell infection and spread of HIV. It has been shown that ARM-HI\'s bind to gp120 and gp-120 expressing cells competitively with CD4, thereby decreasing viral infectivity as shown by an MT-2 cell assay, the binding leading to formation of a ternary complex by recruiting anti-DNP antibodies to bind thereto, the antibodies present in the ternary complex promoting the complement-dependent destruction of the gp120-expressing cells. Compounds and methods are described herein.
Inventor(s): Spiegel; David (New Haven, CT), Parker; Christopher (Medina, OH)
Assignee: YALE UNIVERSITY (New Haven, CT)
Application Number:13/988,251
Patent Claims:see list of patent claims

Details for Patent 9,562,038

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Interferon Sciences ALFERON N INJECTION interferon alfa-n3 VIAL 103158 001 1989-10-10 ➤ Sign Up YALE UNIVERSITY (New Haven, CT) 2030-11-18 RX search
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; SINGLE-USE 103234 001 1989-06-01 ➤ Sign Up YALE UNIVERSITY (New Haven, CT) 2030-11-18 RX search
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; MULTIDOSE 103234 002 1989-06-01 ➤ Sign Up YALE UNIVERSITY (New Haven, CT) 2030-11-18 RX search
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; MULTIDOSE 103234 003 1989-06-01 ➤ Sign Up YALE UNIVERSITY (New Haven, CT) 2030-11-18 RX search
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; SINGLE-USE 103234 004 1989-06-01 ➤ Sign Up YALE UNIVERSITY (New Haven, CT) 2030-11-18 RX search
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; SINGLE-USE 103234 005 1989-06-01 ➤ Sign Up YALE UNIVERSITY (New Haven, CT) 2030-11-18 RX search
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; SINGLE-USE 103234 006 1989-06-01 ➤ Sign Up YALE UNIVERSITY (New Haven, CT) 2030-11-18 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Daiichi Sankyo
Citi
Deloitte
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.